New York Comprehensive Thalassemia Center
Found 15 results
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is P  [Clear All Filters]
Journal Article
Goel R, Patel EU, Cushing MM, Frank SM, Ness PM, Takemoto CM, Vasovic LV, Sheth S, Nellis ME, Shaz B et al..  2018.  Association of Perioperative Red Blood Cell Transfusions With Venous Thromboembolism in a North American Registry.. JAMA Surg. 153(9):826-833.
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
Hoshino A, Kim HSang, Bojmar L, Gyan KEnnu, Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H, Heissel S et al..  2020.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.. Cell. 182(4):1044-1061.e18.
van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.
van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.
Jafari R, Sheth S, Spincemaille P, Nguyen TD, Prince MR, Wen Y, Guo Y, Deh K, Liu Z, Margolis D et al..  2019.  Rapid automated liver quantitative susceptibility mapping.. J Magn Reson Imaging. 50(3):725-732.
Badawy SM, Kattamis A, Ezzat H, Deschamps B, Sicard E, Fradette C, Zhao F, Tricta F, Tsang YChung, Sheth S et al..  2022.  The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.. Br J Haematol. 197(1):e12-e15.
Betts M, Flight PA, L Paramore C, Tian L, Milenković D, Sheth S.  2020.  Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.. Clin Ther. 42(2):322-337.e2.